anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A surface which carries a material which is infected with prions is cleaned with an alkaline cleaning solution to remove as much proteinaceous material as possible from the surface. The cleaning agent is an alkaline cleaning agent which attacks prions remaining on the surface and which attacks prions removed from the surface during the cleaning step. After the cleaning solution is drained, a solution of surfactants, buffers, and heavy metal free corrosion inhibitors is circulated over the surface at 50°-60° C. The surfactants disperse and unclump the prion-contaminated material. A strong oxidant, preferably peracetic acid, is added to the solution to bring the peracetic acid concentration to 1,000-2,500 ppm. The peracetic acid or other strong oxidant attacks the prions, particularly the unclumped prion strands, deactivating the prions. After rinsing and drying, the surface may be wrapped in a microbe impermeable barrier and subjected to terminal sterilization, such as steam autoclaving.
Dental implantation systems and methods are provided, including a system comprising a patient-interacting device having an instrument for preparing a site within a patient's mouth for a dental implant. A guiding device in communication with a fiducial marker engaged with the patient's mouth receives the patient-interacting device, and guides the instrument, relative to the fiducial marker, in conjunction with user manipulation of the patient-interacting device. A controller device including a processor is in communication with the guiding device, and directs the patient-interacting device via the guiding device to prepare the site to receive the dental implant. An engagement sensor is operably engaged with the patient-interacting device and communicates with the controller device. The controller device is responsive to sensed disengagement between the patient-interacting device and the user to direct the guiding device to maintain the patient-interacting device at a minimum vertical disposition. Associated systems and methods are also provided.
Orally administrable granules comprise paraaminosalicylic acid or its salts or esters embedded in a fat.  Isonicotinic acid hydrazide and conventional binders, e.g. water-soluble starch or cellulose derivatives may optionally be included.  The granules, which may optionally be coated, e.g. with shellac, sugar or cellulose derivatives may be prepared by mixing together the active material and fat, adding the binder and moulding the mixture into "strings" which are broken up into substantially cylindrical granules, e.g. by cutting or crushing followed, if desired, by coating by conventional means with conventional enteric coatings, e.g. of shellac or cellulose derivatives.  The preferred fat is lard.  Others which may be used are synthetic glycerides of fatty acids (preferably of single acids) and other natural fats, e.g. whale or coconut oil which may be hardened by hydrogenation.
(1) Background: Dysregulated serum amino acids (AA) are known to be associated with obesity and risk of Type 2 Diabetes (T2D) in adults, and recent studies support the same notion in the pubertal age. It is, however, unknown whether childhood overweight may already display alterations of circulating AA. (2) Methods: We used liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS)-targeted metabolomics to determine plasma concentrations of AA and AA-related molecules in 36 children aged 7-12 years with normal weight or overweight. Clinical and anthropometric parameters were measured. (3) Results: Overweight in children is associated with an altered AA profile, with increased branched-chain amino acids (BCAA) and decreased glycine levels, with no clinically manifested metabolic conditions. Moreover, z-BMI was positively and negatively correlated with BCAA and glycine levels, respectively, even after adjustment for age and gender. We also found a correlation between the AA profile and clinical parameters such as lipids profile and glycemia. (4) Conclusions: A pattern of low glycine, and increased BCAA is correlated to z-BMI, total cholesterol, and triglycerides in overweight but otherwise healthy children. Our data suggest that, in childhood overweight, AA disturbances may precede other clinical parameters, thus providing an early indicator for the later development of metabolic disease.
BACKGROUND: Pheochromocytoma (PCC) is a rare neuroendocrine tumor. Angiogenesis is primary contributing factor for tumorigenesis. Cytochrome c oxidase 4I2 (COX4I2) has been confirmed to take part in the progression of cancer. Hypoxia-inducible factor 1A (HIF1A) is the main regulatory factor for the steady-state response of hypoxia, involved in metabolism and angiogenesis. In this study, we intended to explore the functions of COX4I2 in PCC and the effect mechanism between HIF1A and COX4I2.
MATERIALS AND METHODS: The RNA-sequencing and immunohistochemistry tested COX4I2 expression in highly vascular PCC. Small interfering RNA (siRNA) was used to reduce the mRNA expression of COX4I2, and a small molecule inhibitor was utilized to reduce the protein expression of HIF1A. Culturing cells in 1% O2environment was performed to activate HIF1A. Western blot was applied to quantify the expression of target genes at the protein levels. The supernatant from PCC cells and fibroblasts acted as the conditioned medium. We conducted the tube formation and transwell assays in human vascular endothelial cells (HUVECs) to determine angiogenesis, the binding of COX4I2 promoter and HIF1A was evaluated by the dual luciferase reporter assay.
RESULTS: COX4I2 had been rigorously shown to be overexpressed in highly vascular PCC. Knockdown of COX4I2 in PCC cells (MPC) did not significantly impact angiogenesis, while knockdown of COX4I2 in fibroblast (3T3) notably inhibited angiogenesis. RNA sequencing suggested that the expression of 11 vascular markers, such as CD34 and angiogenesis associated pathways in 3T3, decreased with knockdown of COX4I2. HIF1A had been shown to enhance the mRNA expression of COX4I2 through transcriptional regulation. Activation and inhibition of HIF1A resulted in upregulation and downregulation of COX4I2, respectively. The HIF1A inhibitor demonstrated a reduction in angiogenesis.
CONCLUSION: COX4I2 is overexpressed in highly vascular PCC and contributes to angiogenesis in fibroblasts. Mechanistically, HIF1A transcriptional regulation enhances COX4I2 and its effects on angiogenesis in PCC. COX4I2 might serve as a vascular marker and represent a potential target for vascular therapy.
ABSTRACT OF THE DISCLOSURE     Agents for the arrest of infections resulting from organism growth in contact with an iron-containing body fluid.  The agents are capable of immobilizing the body fluid so that the iron it contains is nutritionally unavailable for the organism.  In the instance where the body fluid is blood, the agent may be administered in amounts effective to bind all of the available red blood cells or hemoglobin, to pre-vent breakdown of either and consequent release of iron to the organism.            The agents preferably include materials capable of binding red blood cells and iron, such as haptoglobin, colloidal silica, anion exchange resins and mixtures thereof.  Preferably, colloidal silica is used either alone or in a composite with a polyolefin elastomer such as polyisobutylene.            The agents may be coated on carriers or substrates, such as gauze pads, tampons and the like, and may be thus utilized topically, as well as intraperitoneally.
Liquiritin (LQ), a kind of flavonoid isolated from licorice, was proven to have great potential in treating heart failure. Pharmacokinetic evaluation is important for demonstrating clinical efficacy and mechanisms, and the prototype drug and its metabolite profiling are important for drug discovery and development. However, the metabolism of LQ in acute myocardial infarction (AMI) model rats still needs to be studied in depth. An information-dependent acquisition (IDA)-ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was applied to profile LQ metabolites in AMI model rat plasma. Protein precipitation and extraction were used for sample preparation. Chromatographic separation was achieved using an XSelect BEH C18 column (2.1 × 150 mm, 2.5 μm) using gradient elution method combining 0.1% formic acid and acetonitrile with a flow rate of 0.3 mL/min. Twelve metabolites were identified in IDA mode, sulfation, glucuronidation, methylation, methyl esterification, glutamine conjugation, and valine conjugation, and their composite reactions were presumed as the primary pathways of LQ metabolism. The variation in the peak areas showed that the time to reach the peak drug concentration of LQ and 12 metabolites was within 5 h. In summary, IDA-bridged UHPLC-MS/MS from characteristic fragment ions toward confidence-enhanced identification could effectively screen and profile metabolites.
The invention provides lactobacillus reuteri ZJUIDS09 for relieving ulcerative colitis and application thereof. The classification of this strain was named: lactobacillus reuteri (Lactobacillus reuteri) with a preservation number of CGMCC No.22843. The lactobacillus reuteri ZJUIDS09 can improve the damage of colonic mucosa and reduce the expression of inflammatory factors in colon by relieving the symptoms of ulcerative colitis. The strain provided by the invention has the capability of tolerating high osmotic pressure and artificial gastric juice, can be efficiently adhered to intestinal epithelial cells Caco-2, and promotes development of intestinal villi. The lactobacillus reuteri ZJUIDS09 can be applied to preparation of products for relieving ulcerative colitis. The product is composed of or derived from lactobacillus reuteri ZJUIDS09, and comprises fermented food, or a probiotic preparation, a medicament or a pharmaceutical composition containing the lactobacillus.
PROBLEM TO BE SOLVED: To provide a series of quinolin derivatives useful for treating an excessive proliferative disease (e.g. cancer) of a mammal, a method of using the compounds for treatment of the excessive proliferative disease of the mammal (especially human) and a medicinal composition including the compounds. SOLUTION: This invention relates to the compounds expressed by formula, pharmaceutically permissible salts and solvates of the compounds. (Y, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are each has a meaning defined in the detailed description.) This invention also relates to the medicinal composition including the compounds and the use of the compounds for inhibition of an abnormal proliferation of cell in the mammal. The compound of the prescribed formula has an activity as an inhibitor for farnesyl protein transferase.
The study included patients with severe head and neck deformity treated by our reconstructive team from Jun 2018 to Jun 2021, with monoblock pre-expanded flaps from the anterior chest, abdomen or back. For flap harvested from the chest, flap prefabrication was conducted in the first stage. In brief, the full length of the descending branch of the lateral circumflex femoral artery, vein and surrounding fascia were harvested and transferred as a free vascular carrier to the subcutaneous space on the anterior thoracic region. The pedicle vessels were anastomosed to the superior thyroid or facial vessels. A rectangular tissue expander was placed underneath the vascular carrier for expansion. In the second stage, the prefabricated flap was transferred to the pedicle vessel to replace the facial defects. Notably, dominant perforators were detected preoperatively and preserved during flap harvest for potential vascular anastomosis. For flaps from the abdomen and back, flaps were harvested as multi-pedicle free flaps. Exclusion criteria included severe liver, kidney or lung insufficiency, and allergy to iodine products.

Upon flap transfer to the face, a 2 mL bolus of ICG (2.5mg/mL) was administrated intravenously and the fluorescence signals were detected by a SPY imaging system (Novadaq Technologies, Inc., Canada). The course of each nourishing vessels and their respective perfusion territory were assessed. During flap fenestration, the opening of oral orifice was given the highest priority, followed by nostrils and palpebral orifices. If the region intended for flap fenestration was well perfused and did not contain major communicating branches or the penetration point of perforators, orifices would be opened directly. In the event of insufficient blood supply, additional vascular anastomosis would be considered for perfusion augmentation, and ICGA would be reconducted for evaluation.

The hemodynamic analysis of flaps was performed before and after fenestration using the incorporated SPY-Q software. The patients' aesthetic and functional recovery were evaluated, as well as postoperative complications including vascular crisis, infection, and flap necrosis.
In this study, we investigated the role of the noncanonical pyroptosis pathway in the progression of lethal sepsis. Our findings emphasize the significance of noncanonical pyroptosis in monocytes/macrophages for the survival of septic mice. We observed that inhibiting pyroptosis alone significantly improved the survival rate of septic mice and that the HMGB1 A box effectively suppressed this noncanonical pyroptosis, thereby enhancing the survival of septic mice. Additionally, our cell in vitro experiments unveiled that frHMGB1, originating from lipopolysaccharide-carrying histiocytes, entered macrophages via RAGE, resulting in the direct activation of caspase 11 and the induction of noncanonical pyroptosis. Notably, A box's competitive binding with lipopolysaccharide impeded its entry into the cell cytosol. These findings reveal potential therapeutic strategies for slowing the progression of lethal sepsis by modulating the noncanonical pyroptosis pathway.
PURPOSE: The aims of this study were (1) to compare "front" and "rear" methods for loading Descemet membrane endothelial keratoplasty (DMEK) tissue into both micro-Jones and standard-Jones tubes and (2) to evaluate the efficacy of a cone-shaped glass funnel adapter designed to make loading DMEK tissue safer for corneal endothelial cells.
METHODS: The corneal endothelium was stained with 0.06% trypan blue to confirm equivalence between mate corneas. The tissues were then processed using the Iowa Lions Eye Bank standard DMEK protocol. In comparison 1, one mate was loaded into the rear of a micro-Jones or standard-Jones tube and the other was loaded into the front of the same tube. In comparison 2, one mate was loaded into the front of the micro-Jones tube and the other was loaded through the cone-shaped funnel adapter into the rear. All tissues were ejected through the front of the modified Jones tubes and assessed for endothelial cell loss (ECL) with calcein AM staining, FIJI, and Trainable Weka Segmentation; scroll widths were measured digitally.
RESULTS: There were no statistically significant differences in ECL between front and rear loading [micro (N = 6 pairs): front 15.74% vs. rear 17.95%; standard (N = 6 pairs): front 19.58% vs. rear 19.17%; all P > 0.05]. DMEK scrolls loaded with the funnel adapter exhibited lower ECL compared with scrolls loaded through the front [micro (N = 8 pairs): front 13.53% vs. loading funnel 2.40%; P < 0.001]. Loading with the adapter was not faster (front 6.66 seconds vs. loading funnel 5.52 seconds; P = 0.24).
CONCLUSIONS: Using a cone-shaped DMEK loading funnel may reduce ECL sustained during preloading.
The invention discloses application of ceramide in preparation of an anti-hepatic fibrosis medicine. The ceramide is C2cer or C6cer. According to the results, C2cer and C6cer can restrain HSC (Hepatic Stellate Cell) multiplication, the effects of C2cer and C6cer are in a dose-effect relationship and a time-effect relationship, and the effect of C6cer is stronger; and C2cer and C6cer can restrain HSC secretion/ can generate collagen. The Cer expressed by the HSC is increased by virtue of C6cer, but the alpha SMA expression is restrained. The C2cer prophylactic medicine can be used for preventing ConA-induced mouse hepatic fibrosis, lowering the content of hepatic collagen, hepatic fibrosis degree scouring and aging, reducing a rat death rate at the early stage of the liver injury, restraining hepatic tissue alphas SMA expression and increasing Cer expression, especially film expression. The conclusion is as follows: the ceramide (C2cer and C6cer) has anti-hepatic fibrosis effect, can be prepared into liposome embedding medium, capsule or injection for clinically preventing hepatic fibrosis.
OBJECTIVES: Non-celiac wheat sensitivity (NCWS) is an emerging clinical condition characterized by gastrointestinal and extraintestinal symptoms following the ingestion of gluten-containing foods in patients without celiac disease (CD) or wheat allergy. Despite the great interest for NCWS, the genetic risk factors still need to be fully clarified. In this study, we first assessed the possible contribution of KIR genes and KIR haplotypes on the genetic predisposition to NCWS.
METHODS: Fifty patients with NCWS, 50 patients with CD, and 50 healthy controls (HC) were included in this study. KIR genes and KIR genotyping were investigated in all subjects by polymerase chain reaction with the sequence oligonucleotide probe (PCR-SSOP) method using Luminex technology.
RESULTS: We found a statistically different distribution of some KIR genes among NCWS, CD, and HC. Specifically, NCWS showed a decreased frequency of KIR2DL1, -2DL3, -2DL5, -2DS2, -2DS3, -2DS4, -2DS5, and -3DS1 genes, and an increased frequency of -3DL1 gene respect to both CD and HC. No difference was detected in the KIR haplotype expression. At the multivariate analysis, KIR2DL5, -2DS4, and -2DS5 were independent predictors of NCWS.
CONCLUSIONS: Our findings suggest a role of KIR genes in NCWS susceptibility, with KIR2DL5, -2DS4, and -2DS5 having a protective effect. Further large-scale multicentric studies are required to validate these preliminary findings.
The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.
FIELD: medicine. SUBSTANCE: method involves administering unloading and ordinary diets alternating in a manner that one week has five unloading and 2 loading diet days with total treatment duration being equal to 12 weeks. The unloading day feeding is carried out with nutrient mixture of Doctor Slim administered as a 15 g large portion of the mixture dissolved in 200 ml of warm water instead of breakfast, dinner, before supper and when going to bed. The supper food is composed of low fat contents ingredients with total fat contents being not greater than 8-10 g. Raw or boiled vegetables except of potatoes are optionally given as addition to breakfast and dinner in the amount of 400 g. Commonly consumed products are given in ordinary diet days without flour and sweet food consumption being increased and with daily consumption of fat restricted to 35-40 g per day. The Doctor Slim mixture is given a portion twice a day before the dinner and supper. EFFECT: improved withstanding of treatment course; enhanced effectiveness of treatment. 2 tbl
Subjects were divided in two groups: a control group and an experimental one. Before the intervention of physical exercise program, subjects performed a Tapping Pedal Test to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
Patients undergo \[\^18F\] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to \[\^18F\] FES PET scan.
Aminoglycosides are toxic antibiotics, but they are urgently needed to treat newborns with severe infections. Aminoglycosides are well known for their nephrotoxicity and ototoxicity, meanwhile the renal function of the newborns is not yet fully developed.The aminoglycoside dosage currently applied in Indonesia is derived from studies done in Caucasian populations. The safety and efficacy of this dosage regimen, however, have never been evaluated till date. The pharmacokinetic profile of drugs may vary between populations and this may be influenced by genetic factors, lifestyle, drug interactions, etc. The detection of aminoglycoside toxicity in newborns is usually problematic. The present study aims to know the proportion of nephrotoxicity and ototoxicity in newborns in the Cipto Mangunkusumo Hospital treated with gentamicin or amikacin in relation to their trough serum concentration. The serum level of gentamicin and amikacin is assumed to be safe if the trough serum concentrations are \< 2 mcg/mL and effective if its is between 5-12 mcg/mL. For amikacin the desired trough serum concentrations are \<10 mcg/mL and the peak is between 20-30 mcg/mL. The nephrotoxicity was assessed by measuring the level of kidney injury molecule-1 in urine while the ototoxicity was assessed by Distortion Product Otoacoustic Emission (DPOE) instrument.
The invention relates to the field of research on Alzheimer's disease-related diseases, and particularly discloses application of knocking out an inflammatory receptor in Alzheimer's disease treatment. Application of an inflammatory receptor C3aR antagonist in preparing a medicament for preventing and treating Alzheimer's disease osteoporosis. Application of an inflammation receptor RAGE antagonist in preparing a medicament for preventing and treating Alzheimer's disease osteoporosis. Application of C3aR-RAGE combined antagonist in preparing medicine for preventing and treating Alzheimer's disease osteoporosis. Application of C3aR antagonist-RAGE antagonist combination in preparation of medicine for preventing and treating Alzheimer's disease osteoporosis. Application of C3a activation inhibitor in preparing medicine for preventing and treating Alzheimer's disease osteoporosis is provided. A medicament for preventing and treating Alzheimer's disease osteoporosis, which comprises a C3aR antagonist-RAGE antagonist combination and/or a C3aR-RAGE combined antagonist. According to the invention, a corresponding treatment scheme and a product are provided for the osteoporosis of the Alzheimer disease, and research is carried out on part of combined medicines in the osteoporosis, so that the treatment effect is obviously improved.
Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 6 months.
Patients with carcinoma of the esophagus or gastroesophageal junction who are suitable for curative intent trimodality therapy will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously weekly for 5 weeks. External beam RT in 5 fractions over 1 week will be delivered any time between week 3-5 of chemotherapy. Ideally patients should get radiotherapy during week 3 of chemotherapy but delivery during week 4-5 is permissible with documentation of the minor deviation. RT must start within 30 calendar days of signing the informed consent form. While restaging imaging is done as per institutional guidelines, ideally patients should get a PET/CT 6 weeks post chemoradiotherapy. Patient will then go for esophagectomy 6-12 weeks after the completion of chemoradiotherapy, but ideally at 6-8 weeks post chemoradiotherapy. Patients will be assessed for acute toxicity weekly during neoadjuvant therapy and then biweekly until esophagectomy. One month after surgery, patient will have a final clinical follow up with the radiation oncologist and review any post-operative complications.